Details:
ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress granules.
Lead Product(s): ABBV-CLS-7262
Therapeutic Area: Neurology Product Name: ABBV-CLS-7262
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
Under the collaboration, Bristol will obtain the exclusive worldwide commercial rights for PRX005, a best-in-class anti-tau antibody that specifically binds with high affinity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R tau isoforms.
Lead Product(s): PRX005
Therapeutic Area: Neurology Product Name: PRX005
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2023
Details:
PRX005 is an anti-tau antibody that specically binds with high anity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R tau isoforms. Neurobrillary tangles composed of misfolded tau proteins, with amyloid beta plaques in alzheimer’s disease.
Lead Product(s): PRX005
Therapeutic Area: Neurology Product Name: PRX005
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
Preclinical data have also demonstrated clearance of both pyroglutamate modified and unmodified Aβ plaque in brain tissue at concentrations of PRX012 estimated to be clinically achievable in the central nervous system with subcutaneous delivery.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Preclinical data have shown that PRX012 binds to beta amyloid plaques and oligomers with high avidity, enabling effective levels of Aβ plaque occupancy at relatively lower dose ranges, which are optimal for subcutaneous delivery.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.
Lead Product(s): Inzomelid
Therapeutic Area: Neurology Product Name: IZD174
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $441.9 million
Deal Type: Acquisition September 21, 2020